Efficacy and safety of 6 or 8weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

Sulkowski, MS; Feld, JJ; Lawitz, E; Felizarta, F; Corregidor, AM; Khalid, O; Ghalib, R; Smith, WB; Van Eygen, V; Luo, D; Vijgen, L; Gamil, M; Kakuda, TN; Ouwerkerk-Mahadevan, S; Van Remoortere, P; Beumont, M

Sulkowski, MS (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.; Sulkowski, MS (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Hepatol Gastroenterol, Baltimore, MD 21205 USA.

JOURNAL OF VIRAL HEPATITIS, 2018; 25 (6): 631

Abstract

The phase 2, open-label ACCORDION (ClinicalTrials.gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week reg......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索